Penumbra SG&A Expenses 2014-2025 | PEN
Penumbra annual/quarterly sg&a expenses history and growth rate from 2014 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Penumbra sg&a expenses for the quarter ending March 31, 2025 were $0.153B, a 6.26% increase year-over-year.
- Penumbra sg&a expenses for the twelve months ending March 31, 2025 were $0.583B, a 10.47% increase year-over-year.
- Penumbra annual sg&a expenses for 2024 were $0.574B, a 13.33% increase from 2023.
- Penumbra annual sg&a expenses for 2023 were $0.506B, a 12.62% increase from 2022.
- Penumbra annual sg&a expenses for 2022 were $0.45B, a 18.87% increase from 2021.
| Penumbra Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $574 |
| 2023 | $506 |
| 2022 | $450 |
| 2021 | $378 |
| 2020 | $287 |
| 2019 | $273 |
| 2018 | $226 |
| 2017 | $184 |
| 2016 | $148 |
| 2015 | $102 |
| 2014 | $64 |
| 2013 | $45 |
| Penumbra Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | $153 |
| 2024-12-31 | $148 |
| 2024-09-30 | $140 |
| 2024-06-30 | $142 |
| 2024-03-31 | $144 |
| 2023-12-31 | $130 |
| 2023-09-30 | $126 |
| 2023-06-30 | $127 |
| 2023-03-31 | $123 |
| 2022-12-31 | $116 |
| 2022-09-30 | $109 |
| 2022-06-30 | $115 |
| 2022-03-31 | $111 |
| 2021-12-31 | $114 |
| 2021-09-30 | $94 |
| 2021-06-30 | $91 |
| 2021-03-31 | $80 |
| 2020-12-31 | $77 |
| 2020-09-30 | $76 |
| 2020-06-30 | $60 |
| 2020-03-31 | $74 |
| 2019-12-31 | $75 |
| 2019-09-30 | $69 |
| 2019-06-30 | $68 |
| 2019-03-31 | $61 |
| 2018-12-31 | $61 |
| 2018-09-30 | $56 |
| 2018-06-30 | $55 |
| 2018-03-31 | $54 |
| 2017-12-31 | $51 |
| 2017-09-30 | $46 |
| 2017-06-30 | $44 |
| 2017-03-31 | $43 |
| 2016-12-31 | $42 |
| 2016-09-30 | $38 |
| 2016-06-30 | $36 |
| 2016-03-31 | $33 |
| 2015-12-31 | $29 |
| 2015-09-30 | $27 |
| 2015-06-30 | $26 |
| 2015-03-31 | $20 |
| 2014-12-31 | |
| 2014-09-30 | $17 |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $11.301B | $1.195B |
| Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. | |||